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Abstract
Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor (C1-INH) is a rare, life-threatening
disorder. It is characterized by attacks of angioedema involving the skin and/or the mucosa of the upper airways,
as well as the intestinal mucosa. In approximately 50 per cent of cases, clinical manifestations may appear during
childhood. The complex management of HAE in pediatric patients is in many respects different from the manage-
ment of adults. Establishing the diagnosis early, preferably before the onset of clinical symptoms, is essential in
cases with a positive family history. Complement studies usually afford accurate diagnosis, whereas molecular
genetics tests may prove helpful in uncertain cases. Appropriate therapy, supported by counselling, suitable modifi-
cation of lifestyle, and avoidance of triggering factors (which primarily include mechanical trauma, mental stress
and airway infections in children) may spare the patient unnecessary surgery and may prevent mortality. Prompt
control of edematous attacks, short-term prophylaxis and intermittent therapy are recommended as the primary
means for the management of pediatric cases. Medicinal products currently used for the treatment of children
with hereditary angioedema include antifibrinolytics, attenuated androgens, and C1-INH replacement therapy. Cur-
rent guidelines favour antifibrinolytics for long-term prophylaxis because of their favorable safety profile but effi-
cacy may be lacking. Attenuated androgens administered in the lowest effective dose are another option. C1-INH
replacement therapy is also an effective and safe agent for children. Regular monitoring and follow-up of patients
are necessary.
1. Introduction
The deficiency of the C1 inhibitor (C1-INH) is inherited
as an autosomal dominant trait. It causes hereditary
angioedema (HAE-C1-INH), which is regarded as an
uncommon disorder characterized by recurrent angioe-
dematous episodes involving the subcutis and/or the
mucosa of the upper airways and the gastrointestinal
tract [1]. Uncontrolled activation of enzymes belonging
to various plasma cascades (such as the complement,
fibrinolytic, coagulation, and kinin systems) leads to the
release of bradykinin, which contributes angioedema for-
mation by enhancing capillary permeability [2]. The
diagnosis of HAE-C1-INH is established by its clinical
manifestations, the family history, as well as the findings
of complement and molecular genetics studies. Its man-
agement consists of the prevention of edematous epi-
sodes, as well as the control of acute attacks [3-5]. The
range of medicinal products used for prophylaxis
(antifibrinolytics, attenuated androgens, and C1-INH
concentrate) has not changed for decades. The prophy-
lactic use of plasma-derived C1-INH (pdC1-INH), how-
ever, has increased owing to wider availability and other
options for emergency intervention have also increased.
A kallikrein inhibitor (ecallantide) and a bradykinin B2
receptor antagonist (icatibant) have been introduced to
clinical practice and recombinant C1-INH product is
under investigation [6,7]. Although the complex man-
agement of HAE-C1-INH is in many respects different
in children compared to adults, the principles of pedia-
tric therapy are poorly supported by published data with
the majority of publications being case reports. The fol-
lowing discussion provides a literature review focused
on the hallmarks of pediatric HAE-C1-INH, illustrated
by the experience accumulated by the Hungarian HAE
Center during the follow-up of 49 children with Type I
or Type II HAE-C1-INH (23 males and 26 females with
a median age of 6 [4-11] years at diagnosis) from diag-
nosis to the age of 18 years. Correspondence: farkash@kut.sote.hu
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In 50 per cent of HAE-C1-INH patients, the manifes-
tations of HAE-C1-INH first occur during childhood.
Therefore, establishing the diagnosis early and initiat-
ing follow-up care as soon as possible are indispensa-
ble for preserving the patients quality of life. The
occurrence of edematous manifestations in other mem-
bers of the patient’s family may assist diagnosis. This
clue is present in 75 to 85 per cent of cases, whereas
in the remaining 15 to 25 per cent, HAE-C1-INH
results from a new gene mutation [1]. Within our
study population of 49 pediatric patients from 31
families, HAE-C1-INH was diagnosed in first-degree
r e l a t i v e so f4 1c h i l d r e n( 8 4 % )a n dan e wm u t a t i o nw a s
diagnosed in 8 subjects (16%). According to the Men-
delian rules of autosomal inheritance, the offspring of
a HAE-C1-INH patient have a 50-per-cent chance of
inheriting the disease. Therefore, it is important to
establish the diagnosis as early as possible before the
onset of clinical manifestations.
2.1. Prenatal diagnostics
Prenatal diagnostics may recognize fetal abnormalities
requiring intervention in utero or during the neonatal
period, along with those justifying the termination of
pregnancy. Additionally, this diagnostic modality enables
parents at genetic risk to avoid passing heritable diseases
to their offspring or negative findings may encourage
them to have unaffected children. Notwithstanding this,
t h er o u t i n eu s eo fp r e n a t a ld i a g n o s t i c si nH A E - C 1 - I N H
patients is impractical for several reasons. No mutation
of the C1-INH gene can be detected in 8 to 10 per cent
of cases [8,9]. Identical mutations may be associated
with substantially different phenotypes. Additionally,
mutation of the C1-INH gene itself may not be a valid
indication for terminating pregnancy because it may
cause a non-fatal, manageable disease in the offspring,
the severity of which may not be predicted in advance.
Therefore, abortion should be decided by the mother
afflicted by HAE-C1-INH following the evaluation of
benefits and risks. Naturally, prenatal diagnostics invol-
ving chorionic villous sampling (on weeks 10 to 12) or
amniocentesis (on weeks 16 to 18 of gestation) is war-
ranted in the presence of additional risk factors (such as
advanced maternal age, AFP abnormality, ultrasound
findings suggestive of fetal malformation, atypical num-
ber of chromosomes).
Every patient registered with the Hungarian HAE
Center undergoes testing of the C1-INH gene at the
molecular genetics laboratory of the institution. The
data thus obtained are collected in an international,
locus-specific database [9]. The Center has established a
multidisciplinary team (consisting of an ultrasound
expert, a gynecologist, and a geneticist) for implement-
ing prenatal diagnostics. Remarkably, only a single
patient has contemplated this option but refrained from
using it eventually. The changes of attack frequency dur-
ing the last trimester of pregnancy are of potential prog-
nostic value. According to our observations, pregnancy
with a fetus affected by HAE-C1-INH was associated
with a significant (p = 0.039) increase in the number of
edematous attacks experienced by the mother during
the third trimester [10].
2.2. Postnatal diagnosis
2.2.1. Symptom-free children with a positive family history:
initial screening (including complement tests) is necessary
at the age of 6 months and one year
Type I HAE-C1-INH is characterized by reduced C4, as
well as reduced antigenic and functional C1-INH levels. In
Type II HAE-C1-INH C4 is reduced and antigenic C1-
INH level is high or normal and the functional activity of
C1-INH is reduced [4,5]. Complement concentrations
measured in cord blood from full-term neonates are lower
than maternal levels. Antigenic and functional C1 inhibitor
levels correspond to 70% and 61.8% of adult values,
respectively [11] and increase to the normal level by the
age of 6 months to one year. Therefore, too early testing
may lead to a false diagnosis of HAE-C1-INH. Further-
more, serum complement levels are influenced by birth
weight and gestational age [12,13]. In conformity with
international recommendations, the screening of pediatric
patients with a positive family history is performed at the
Hungarian HAE Center after the age of 6 months and
repeated after the patient has turned one year [5]. Half of
our patients (26 out of 49) were symptom-free at the time
of diagnosis with screening prompted by positive family
history for angioedema (Table 1).
Although HAE-C1-INH results from mutation of the
C1-INH gene, molecular genetic analysis is not a prere-
quisite for diagnosis, as a complement study is sufficient
to recognize the disease [5]. In addition to its funda-
mental role in prenatal diagnostics, molecular genetics
analysis may aid the early diagnosis of uncertain cases at
the age of 1 to 3 years. In our practice, this method has
proven extremely helpful in two children whose C4
levels were normal, whereas C1-INH antigenic concen-
tration and functional activity were borderline low at
initial and follow-up measurements. DNA analysis
detected the mutation identified earlier in the parental
C1-INH gene in both children and thus established the
diagnosis. Subsequently, the characteristic symptoms of
HAE-C1-INH manifested in both children.
2.2.2. HAE-C1-INH suggested by the symptoms of the child
The diagnosis of HAE-C1-INH was suggested by clinical
manifestations in 21 per cent (10/49) of our pediatric
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interfered with the recognition of the hereditary disorder
(Table 1). Following the identification of affected par-
ents, family screening led to diagnosing HAE-C1-INH in
26 per cent (13/49) of children exhibiting edematous
symptoms (previously attributed to allergy). In 9.2 per
cent (4/49) of cases, establishing the diagnosis of HAE-
C1-INH in the offspring shed light on the obscure etiol-
ogy of edematous episodes experienced by either parent
or identified the latter as an asymptomatic carrier. The
‘lag period’ between the onset of symptoms and
the diagnosis of HAE-C1-INH (an efficiency marker of
the health care delivery system managing the patients) is
highly variable among different countries. The mean
duration of this lag period until diagnosis is 21 years
according to FRANK [14] and 16.3 years according to
BYGUM [15]. By contrast, it was 11.2 years in our study
population and very short - just 2.36 years - in the sub-
set of symptomatic children. The latter is explained by
the fact that the complete range of complement tests
are performed at the HAE-C1-INH Center on every
patient with angioedema of unknown etiology.
Clinical manifestations Although angioedematous epi-
sodes may occur at any age, these usually begin between
5 and 11 years. Mean age at disease onset was found to
be 11.2 years by BORK [16], 9.5 years by, BYGUM[15],
and 4.4 years by MARTINEZ [17], whereas it was 6.6
years in our patient population. Clinical symptoms are
extremely uncommon during infancy [11]. Edema may
involve the subcutis or/and the submucosa. Subcuta-
neous edema appears on the extremities, the face, neck,
torso and genitals as a non-pruritic and non-erythema-
tous lesion. It is the most common and the earliest loca-
lization in pediatric patients: it was the initial
manifestation of HAE-C1-INH in 27 of our 49 patients.
Subcutaneous angioedema usually resolves sponta-
neously within 2 to 4 days [16].
When angioedema involves the larynx, submucosal
edema of the upper airways can lead to asphyxia. The
visual appearance of edema is not different from that
seen in upper airway edema (UAE) of other inflamma-
tory or allergic etiologies. According to case reports
published in the literature, it was misdiagnosed as
edema caused by allergic asthma in a three-year-old girl
[18] and mistaken for epiglottitis in another child [19].
However, there is a helpful differential diagnostic clue:
standard medications used to relieve airway edema
(such as glucocorticoids, antihistamines, and epinephr-
ine), which usually accomplish dramatic improvement in
children compared to adults, tend to be ineffective in
reducing the swelling related to HAE [20,21]. In com-
parison to adults, asphyxia may ensue more rapidly in
children because of smaller airway diameter. Addition-
ally, laryngoscopy is more difficult to perform in small
children owing to the lack of co-operation [22]. Angioe-
dema of the larynx is rare: 0.9 per cent of all HAE-
C1-INH attacks. Almost 80 per cent of UAEs occur
between the age of 11 and 45 years, although this condi-
tion has been described in a child as young as 3 years
[23]. In our study population, the earliest time of onset
of UAE was similarly 3 years of age. However, it was
not an initial manifestation in any of our patients. Up to
the age of 18 years, 23 of our 49 patients sustained at
least one attack of UAE and the greatest number of
upper airway episodes experienced by the same patient
was 43. Edema confined to the tongue did not occur in
our patients.
In the gastrointestinal tract, submucosal edema may
be associated with colicky abdominal pain, nausea,
vomiting, watery post-attack diarrhea, occasional pale-
ness of the skin consequent to hypovolemia, prostration,
dehydration, tachyarrhythmia, and fainting and it may
mimic an ‘acute abdominal catastrophe’. Afflicted
patients are usually admitted to a surgical department
for observation and are often subjected to an unneces-
sary operation [24]. The most likely differential diagnos-
tic candidates include acute appendicitis, mesenteric
lymphadenitis, intussusception, strangulation ileus
resulting from intestinal torsion and less often suspected
perforated Meckel’s diverticulum, polycystic ovarian syn-
drome with ovarian torsion, hemorrhage or infarction
[25]. Edema of the intestinal wall may lead to intussus-
ception [26-28].
Recurrent abdominal complaints of unknown etiology
should always raise the suspicion of HAE-C1-INH.
The clinical manifestations of an edematous attack of
Table 1 Demographical data of and the circumstances of establishing the diagnosis in the study population
N° of
patients
Age (median) at
diagnosis
Age at the onset of
symptoms
Boys Girls
Symptom-free, identified by family screening (53%) 13 13 5 (3-11) 6 (4-12)
Symptomatic, identified by family screening undertaken after either parent had
been diagnosed with HAE-C1-INH (26%)
7 6 7 (5-12) 5 (3-10)
Diagnosis established by clinical manifestations (21%) 3 7 9 (4-11) 3 (1-7)
25
th and 75
th percentiles are shown in parentheses.
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abnormalities detectable by diagnostic imaging (ultra-
sound, US; CT; video capsule endoscopy; etc.). Although
US findings (including free peritoneal fluid, edema of the
intestinal wall, and abnormalities of liver structure) are
non-specific to HAE-C1-INH, abdominal US may prove a
sensitive, rapid, and non-invasive differential diagnostic
modality, which is particularly straightforward in pediatric
patients [29,30]. Edematous attacks are not associated
with any specific laboratory abnormality although leukocy-
tosis can occur particularly with hemoconcetration. The
attack is not accompanied by pyrexia and the laboratory
parameters of inflammation are normal. As the edematous
attacks of HAE-C1-INH are associated with elevated pro-
thrombin fragment 1+2 (F1.2) and D-dimer levels, these
indices may serve as objective, but non-specific biomarkers
[31].
An edematous abdominal attack occurred as the initial
manifestation of HAE-C1-INH in 3 of the 49 pediatric
patients. Estimating the prevalence of intestinal edema
in the pediatric population is difficult, because ‘belly
ache’ is a common symptom with a multitude of possi-
ble causes, especially in infants. One to two per cent of
HAE-C1-INH attacks can occur in other localizations
including the urinary bladder, the urethra, muscles and
joints, kidney; pericardial or pleural effusion (known as
the ‘chest episode’) or neurological symptoms [1,16]. In
our study population (n = 49), a ‘chest episode’ evolved
in three and pericardial effusion occurred in one patient
during an attack [32].
The characteristic prodromal sign of erythema mar-
ginatum (appearance of a map-like pattern on the skin)
occurs more frequently during childhood. In a propor-
tion of cases, this lesion can evolve as an independent
phenomenon, without a subsequent attack. In our study
population, this symptom occurred in 42 per cent of
patients [33], whereas BYGUM observed it in 58 per
cent of cases [15]. Its appearance is a potential differen-
tial diagnostic pitfall, because a similar skin lesion can
evolve in viral or bacterial infections, as well as it can be
misdiagnosed as urticaria [34].
The time of onset, frequency, and duration of symp-
toms, as well as the severity of attacks all exhibit inter-
individual variation and substantial differences exist even
within the same family. Analyzing the time of onset of dis-
ease symptoms revealed an increase in the frequency and
severity of manifestations between 3 and 6 years of age, as
well as around puberty. This is probably related to the
manifold physiological (endocrine, mental, and somatic)
changes occurring in these periods of development. In
agreement with the observations of BORK, we found that
the earlier the onset of symptoms, the more severe will be
the subsequent course of HAE-C1-INH [16].
3. Management
Counselling
Counselling the patient and family is the initial step
after diagnosis. Providing the patient and family with
appropriate information is indispensable to adopting a
suitable lifestyle and avoiding severe complications. At
the initial visit, the child and parents are counselled in
person and ongoing consultation is offered using a tele-
phone hotline and the website of the HAE Center
http://www.haenet.hu.The kindergarten or school are
informed of the diagnosis in writing. The patient
receives a multilingual information card to carry at all
times. Additionally, special medication for emergency
use at home during acute edematous attacks is provided,
along with contact information on the self-help organi-
zations of patients.
3.1. Primary prevention
By triggering edematous attacks, certain factors can
influence the time of onset and localization of symp-
toms. Provoking factors include trauma, emotional
stress, surgery or diagnostic manipulation of the head
and neck region, physiological changes of sexual hor-
mones (during puberty, the menstrual cycle or preg-
nancy), changes of the weather, specific foodstuffs and
medicinal products [1]. The incidence of these factors
differs slightly among pediatric and adult patients. The
initial phase of therapy is primary prevention - that is,
the identification and when possible elimination of
triggering factors. The exploration of the latter in our
study population identified mechanical trauma as the
most common provoking factor (52.6%), followed by
mental stress (36.8%), airway infection (36.8%), and
menses (26.7%). By contrast, physical exertion (60.4%),
mental stress (56.6%), mechanical trauma (53.8%),
pregnancy (39.4%), and menses (26.8%) are the most
common triggering factors in adults. A proportion of
attacks can be prevented through appropriate counsel-
ling and changes to lifestyle [10]. This is supported by
our observation that in patients whose disease had
been diagnosed before the onset of symptoms, initial
manifestations occurred later, at the age of 6 (rather
than 4) years. We recommend that children with
HAE-C1-INH participate in sports regularly, but activ-
ities involving direct bodily impact are not recom-
mended. Therefore, only partial exemption from
school gymnastics is advised. Considering that infec-
tion is an important triggering factor in the pediatric
population, infants should not attend peer commu-
nities (e.g. nursery school, kindergarten) during the
period of age-related susceptibility to infections. Heli-
cobacter pylori is another potential provoking factor.
Accordingly, it is expedient to screen patients for
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administer eradication therapy even during childhood
[35].
If despite counselling, the manifestations of HAE-C1-
INH recur with increasing frequency and in more severe
form, it is important to search for other accompanying
disorders. In children, abdominal symptoms and/or neu-
rological signs may suggest celiac disease. Certain med-
icinal products (such as estrogen-containing oral
contraceptives, ACE inhibitors, ARBs) can also induce
the manifestations of HAE-C1-INH. Estrogen containing
contraceptives are not recommended for adolescent
girls. ACEIs and ARBs are widely administered to adult
patients, but data on their pediatric use are limited.
Only two case reports have been published on ACEI-
induced angioedema in children [36,37] and no informa-
tion is available from the literature on pediatric patients
with HAE-C1-INH. Immunizations are usually recom-
mended for children with HAE-C1-INH and the preven-
tion of infections may reduce the frequency of
edematous attacks.
3.2. Drug prophylaxis
As disease manifestation onset usually occurs between 6
to 8 years of age, prophylaxis is extremely uncommon
under the age of 6 years [1]. During this period of life,
emergency therapy of acute attacks is preferred and
pharmacologic intervention should be initiated as early
as possible at the onset of the attack. Other alternative
form of short-term prophylaxis may then be considered.
As regards the pediatric population of HAE-C1-INH
patients diagnosed by our team, 61.23% (30/49) did not
require therapy after diagnosis, owing to the lack of
symptoms.
3.2.1. Short-term prophylaxis
This prophylactic modality involving treatment on a sin-
gle occasion or over several days is intended for the pre-
vention of a single impending attack.
3.2.1.1. ‘Classical’ short-term prophylaxis This type of
prophylaxis is recommended before surgical, diagnostic
interventions contemplated in the head and neck region,
including dental procedures, and other operations per-
formed under endotracheal manipulation, as these may
trigger an edematous attack -UAE primarily [4,5]. The
following agents are appropriate: danazol 5 mg/kg/day
(maximum daily dose is 600 mg); tranexamic acid 20 to
40 mg/kg/day in 2 or 3 divided doses (maximum daily
dose is 3 g) introduced 5 days before and continued for
additional 2 days after the intervention; and C1-INH
concentrate 10 to 20 U/kg administered one hour before
the procedure [5,38]. Fresh frozen or solvent-detergent
plasma may be used only if C1-INH concentrate is not
available [39] and in poor-risk patients undergoing
major surgery. The recommendations by GOMPELS
et al on the duration of prophylaxis and of C1-INH sup-
plementation are at variance with our practice [4].
During childhood, surgical interventions are less fre-
quent, shorter in duration and may not necessarily
require general anesthesia. Operations performed under
intratracheal narcosis were identified in the history of
eleven patients - eight of these had experienced an ede-
matous attack after the intervention before their HAE-
C1-INH was recognized. After diagnosis, short-term
prophylaxis was administered before 5 procedures (ENT
intervention, dental extraction, appendectomy under
ITN) performed in 4 patients. Patients on pre-existing
treatment with tranexamic acid or danazol received
these agents in escalated doses before minor procedures.
Untreated patients received 500 U C1-INH concentrate
one hour before major operations and another 500 U
was kept ready during all such interventions. Short-term
prophylaxis (as above) invariably prevented edema for-
mation; the postoperative period was uneventful and no
complications ensued [10]. Since its marketing authori-
zation in Hungary, only C1-INH concentrate is adminis-
tered at the HAE-C1-INH Center before major surgery
or diagnostic procedures.
3.2.1.2. ‘Alternative’ short-term prophylaxis This type
of prophylaxis is used in the presence of prodromal
symptoms as well as when potentially edema-inducing
pathological, physiological or environmental effects per-
sist for a brief (several-hours/days-long) period only.
Upper respiratory track infections occur frequently dur-
ing childhood and it is important to treat bacterial infec-
tions early and to introduce short-term prophylaxis as
soon as possible and to continue its administration over
the duration of the infection [38]. In our practice, this
type of prophylaxis was occasionally started at an appro-
priate time during the menstrual cycle and continued
for a week - or optionally, a single dose of C1-INH con-
centrate was administered. The choice between these
options depended on the particular phase of the men-
strual cycle, identified as critical (see the agents and
their dosages in the section on ‘classical’ short-term
prophylaxis).
When prodromal symptoms (pruritus, tingling, nausea,
dry mouth, heartburn, diarrhea, anxiety, fatigue,
erythema marginatum, joint-pressure sensation)
occurred, tranexamic acid (40 mg/kg/day) or danazol
(100-200 mg/day) administered over 2 to 3 days reduced
the severity and halved the duration of subcutaneous or
gastrointestinal manifestations [38].
3.2.2. Long-term prophylaxis (LTP)
The literature reveals that the recommendations on
introducing long-term prophylaxis are extremely hetero-
geneous [4,5,14,40-44]. In general, severe or frequently
recurring attacks are considered among the indications
for long-term prophylaxis. UAE in the patient’sh i s t o r y
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[4,5,40,42]. The methods for determining attack fre-
quency were variable. Daily activities were taken into
account by 4/7 authors [14,40,42,43]. The UK guideline
added the requirement of “concentrate administration”
as an additional criterion (although “acute treatment”
would have been more appropriate). Limited access to
medical care was mentioned in two proposals [40,42].
Drugs suitable for long-term prophylaxis include anti-
fibrinolytics (epsilon-aminocaproic acid, tranexamic
acid), attenuated androgens (danazol, stanozolol, oxan-
drolone) and C1-INH concentrate [4,5]. Experience with
long-term C1-INH prophylaxis is limited in pediatric
patients. In 2009, a new, plasma-derived C1-INH con-
centrate was approved in the USA for long-term pro-
phylaxis. The expanding range and indications for the
use of C1-INH preparations along with their increasing
availability are expected to encourage the use of - as
well as obtaining further clinical experience with - these
products [45,46]. Currently, consensus statements by
various authorities unanimously advocate tranexamic
acid (TXA) as the agent of choice for long-term prophy-
laxis in children because its safety profile is more favor-
able than that of attenuated androgens [38,47].
Attenuated androgens may be administered when antifi-
brinolytics are ineffective or contraindicated (i.e. for
patients with a history of thromboembolism or a family
history of thrombophilia) [38]. Adverse reactions can be
avoided by administering the lowest effective dose
[48-52].
Androgen side effects include decreased growth rate,
virilization, and behavioral disorders during childhood,
whereas in adolescence, menstruation irregularities and
elevation of serum transaminase levels may occur [53].
Weight gain, myalgia, headache, libido changes, micro-
haematuria, alterations of lipid profile, and the devel-
opment of hepatocellular carcinoma or adenoma are
more characteristic of adult patients, as the safety pro-
file of danazol is related to its dose and the duration
of its use [54].
The number of longitudinal studies into the effective-
ness and adverse effects of LTP is limited in both adult
and pediatric patients. LTP is introduced if UAE has
been detected in the history, as well as the patient has
experienced severe and recurrent attacks with no identi-
fiable triggering factor. After diagnosis, the frequency
and severity of disease manifestations warranted LTP in
18.36% (9/49) of our pediatric patients - in contrast to
the management of adults, where 39% are receiving
LTP. TXA 20 to 40 mg/kg daily was administered in
two or three divided doses (maximum dose: 3 g/day
split 2 or 3 times per day). Before TXA was available,
epsilon-aminocaproic acid (EACA, 0.17-0.43 g/kg per
day) had been used, but it was less well tolerated by
patients than TXA, which is now preferred for initial
prophylaxis.
When antifibrinolytics failed to achieve satisfactory
improvement, caused severe adverse effects, or their use
was contraindicated, treatment with attenuated andro-
gens was introduced according to the Budapest protocol
[5], with titration to the lowest effective dose level.
Treatment with the lowest effective maintenance dose of
danazol (2.5 mg/kg per day; 50 mg/day initial dose) was
started and if effective reducing the dosage interval to
every other day or every third day. If necessary, the dose
was increased to a maximum of 200 mg/day. Potential
adverse effects were monitored.
Danazol was well tolerated by our pediatric patients
[55]. Treatment with this drug was effective; it reduced
the number of attacks significantly during the first year.
Unfortunately, however, the effect of danazol declined
during the 4
th and 5
th years of therapy despite the esca-
lation of its dose and this is similar to our experience
with the treatment of adult patients [10]. Notwithstand-
ing this, the majority of patients treated with these
agents are not completely symptom-free. All patients
treated with C1-INH supplementation received prophy-
laxis with antifibrinolytics or attenuated androgens.
3.2.3. ‘Intermittent’ prophylaxis
Long-term prophylaxis does not necessarily mean unin-
terrupted dosage with the drug over a lifetime -
although this issue is not enlarged upon in consensus
guidelines. On occasion of annually scheduled, regular
check-ups, the therapeutic regimen is modified fre-
quently: drugs are discontinued and others are intro-
duced, as well as their doses are adjusted. Although it is
not mentioned by pertinent guidelines, intermittent pro-
phylaxis may prove effective and safe, especially in the
management of pediatric patients. The technical term
“intermittent prophylaxis” was used in relation to dana-
zol treatment by AGOSTONI as early as in 1978 already
[56]. We used this modality of prophylaxis when a
change occurred in the number or severity of edematous
attacks and although the underlying causes of this
change were suspected, their elimination was not possi-
ble. Additionally, ‘intermittent’ prophylaxis was adminis-
tered during prolonged, critical periods known to be
associated with attacks (such as starting school, exam
periods, outbreaks of upper airway infections, winter
months, family problems, adolescence, pregnancy).
Occasionally, the drugs conventionally used for LTP
were administered in combination with intermittent C1-
INH substitution (1 to 2 × 500 U/week). Intermittent
prophylaxis with C1-INH was introduced when disconti-
nuation of danazol had become necessary owing to lack
of effect or the occurrence of undesirable effects. Inter-
mittent prophylaxis with TXA and C1-INH concentrate
administered to 20.41% (11/49) of our patients
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duration and severity substantially.
3.3. Emergency therapy
The management of full-blown attacks depends on their
localization and severity. The range of drugs suitable for
emergency use has increased over recent years. In addi-
tion to the medicinal products used earlier (antifibrino-
lytics, attenuated androgens, C1-INH concentrate, fresh
frozen or solvent-detergent plasma), icatibant (a bradyki-
nin receptor B2 antagonist) and ecallantide (a kallikrein
inhibitor) have become available in clinical practice and
recombinant C1-INH is under clinical trial. No experi-
ence is available yet with the pediatric use of the latter
three innovative drugs, which differ from previous treat-
ments in dosage, mode of action, and manufacturing
process. By increasing the range of therapeutic alterna-
tives, the introduction of these agents enables medical
professionals to make much mo r es p e c i f i ca n di n d i v i -
dualized decisions in choosing an appropriate treatment
[7]. Owing to their straightforward administration by
subcutaneous injection and prompt effect, both the kal-
likrein inhibitor and the bradykinin receptor antagonist
are expected to prove extremely beneficial for pediatric
patients. In our expectations, treatment with these
agents might obviate the need for introducing long-term
pharmacotherapy and can relieve patients from taking
oral medication continuously and occasionally over a
lifetime.
Although usually resolving spontaneously, subcuta-
neous attacks can be controlled by treatment with antifi-
brinolytics and anabolic steroids. Administering
increased doses of these drugs reduces the duration of
attacks and prevents their escalation. Edema localized to
the extremities does not progress to a severe condition
but in pediatric patients it is a common cause of absen-
teeism from school (and adults from work). Edematous
swelling of the face, lips, neck or torso, as well as sub-
stantial edema of the extremities require special man-
agement. Facial edema may progress and involve the
mucosa of the upper airways. Edema of the neck can
cause complications through compression, whereas sub-
cutaneous swelling on the chest may be accompanied by
pericardial or pleural effusion [16,32,57]. Severe edema
of the extremities is very painful and can interfere with
blood circulation in the affected limb. Following pub-
lished guidelines, we always administered C1-INH con-
centrate, which mitigated symptoms within 30-60
minutes and eliminated them completely over 24 to 48
hours. Treatment with C1-INH concentrate was neces-
sary for edema of the extremities in two pediatric
patients [58].
Edema of the upper airway mucosa is a life-threaten-
ing condition potentially leading to asphyxia, which is
responsible for the 30-to 40-per-cent mortality related
to lack of treatment or delayed diagnosis [59]. Cur-
rently, the administration of C1-INH concentrate is the
only adequate treatment for children with UAE
[4,5,38]. In our practice, edema of the upper airway
mucosa is similarly relieved by administering C1-INH
immediately. The child is then hospitalized until the
complete resolution of symptoms, in an institution
where an ICU is available with ready access to endotra-
cheal intubation (or tracheostomy if needed) and air-
way management. The initial dose of C1-INH
concentrate is 10 to 20 units/kg for pediatric patients
(usually 500 units). Symptoms subsided markedly
within 15 to 30 minutes and resolved completely
within 12 hours after treatment. No recurrence of the
attack nor occurrence of undesirable effects were
observed. Earlier administration of C1-INH during an
attack was followed by more rapid regression. Accord-
ingly, the education of patients was particularly focused
on the accurate description of subjective symptoms of
UAE, stressing that mild dysphagia and globus sensa-
tion are the most common initial manifestations [58].
Edema of the gastrointestinal mucosa requires emer-
gency treatment to relieve acute clinical symptoms
(intense and colicky abdominal pain, nausea and vomit-
ing) and to correct hypovolemia from post-attack watery
diarrhea. Additionally, clinical manifestations may
mimic the signs of an ‘acute abdominal catastrophe’,
which warrants considering the need for surgical inter-
vention. In patients with known HAE-C1-INH, the dra-
matic effect of C1-INH concentrate administered for
abdominal symptoms may be of differential diagnostic
value. In our experience, treatment with this agent is
followed by substantial mitigation of symptoms within
half an hour and their complete resolution within 12 to
24 hours. The abnormalities detected by abdominal US
(such as free peritoneal fluid, edema of the intestinal
wall, ‘starry sky’ pattern in the liver) also resolve within
24 to 48 hours [29,30]. The initial dose of 500 U was
sufficient even in abdominal attacks and repeating this
dose within 4 hours owing to unsatisfactory improve-
ment was necessary in only two children. The maxi-
mum dose should not exceed 20 U/kg. C1-INH is
appropriate for any population and all age groups of
pediatric patients. In view of the increased susceptibility
of children to hypovolemia and considering the substan-
tial extravasation into the peritoneal cavity and the
intestinal lumen, we always administer physiological sal-
ine as parenteral fluid replacement during every abdom-
inal attack. Treatment with C1-INH concentrate has
been effective, not accompanied by adverse effects or
the transmission of infection, nor antibody formation.
We no longer administer fresh frozen plasma since C1-
INH concentrate has become available 20 years ago
[38,58].
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This involves prophylactic or emergency treatment in
the patient’s home, administered by the summoned
health care professional or as self-medication by the
patient or family member. This modality has the advan-
tage of the fastest possible treatment without the delay
incurred by transportation of the patient to a health
care institution. Naturally, a prerequisite to this
approach is to ensure the constant availability of emer-
gency medication in the patient’s home [60-62]. No con-
sensus has been reached yet regarding home-based
management. At the 6
th C1-INH Deficiency Workshop
(held between 22 and 24 May 2009 in Budapest, Hun-
gary) a roundtable conference discussed the topic of
self-injection by patients, in order to lay the foundations
of future international guidelines.
As regards pediatric patients, medication is best admi-
nistered by a health care professional. Expert assessment
of the patient’s condition, observation of symptomatic
improvement, and intravenous drug administration are
best handled by experienced professionals. In case of
UAE, emergency treatment at home should be followed
by hospitalization until symptoms resolve completely.
Admission to hospital is similarly necessary in a severe
abdominal attack, in order to rule out a possible, acute
abdominal emergency. If a life-threatening condition has
occurred and no expert help is available within reason-
able time, the emergency medication may be adminis-
tered by parents, relatives, or older pediatric patients
themselves - on condition that they have acquired the
technique of intravenous injection beforehand [38]. The
success of home-based management of 12 pediatric
patients was reported by MARTINEZ [17]. In Hungary,
C1-INH concentrate was approved in 1996. The Minis-
try of Health has made this medication available free of
charge to all HAE-C1-INH patients. Patients are allowed
to keep the concentrate at home and therefore, it is con-
stantly available at hand for administration by the gen-
eral practitioner on duty or the summoned emergency
medical technician. In Hungary, family practitioners are
authorized to prescribe C1-INH concentrate on proposal
from the principal of the HAE center.
3.5. Follow-up
As HAE is an hereditary disorder and its gene therapy is
not yet available, patients must reconcile themselves to a
lifelong disease experience and prolonged doctor-patient
relationships. The delivery of follow-up care for HAE-
C1-INH patients and the accumulation of data on their
disease and management are best implemented using a
centralized approach [38]. HAE centers should be estab-
lished in consideration of the conditions prevailing in
the country involved. In Hungary, for example, a single
center is sufficient owing to the size of the population
and geographic properties of the country. The National
HAE Center consists of the following five organizational
units: outpatient clinic, inpatient facility for the emer-
gency therapy of adult and pediatric patients, comple-
ment laboratory, molecular genetics laboratory, and the
self-help organization of HAE-C1-INH patients [63]. In
addition to diagnosing HAE-C1-INH accurately, coun-
selling and educating patients, as well as choosing and
prescribing the medication most appropriate for indivi-
dual patients, the Center must also assume the follow-
up care of patients. The latter involves a control visit at
least once a year; however, newly diagnosed patients
and those on LTP should be monitored at 3-month
intervals initially and then, twice a year for the next 2
years. Control visits comprise a laboratory screen,
anthropometric assessment, and abdominal US, as well
as the recording of symptoms and potential undesirable
effects associated with drug treatment (by reviewing
patient diaries and hospital discharge summaries) - all
these afford adjusting therapy and introducing new
treatments as necessary. At the Hungarian HAE Center,
we use mail notification to summon patients for control
visits (minors are to be accompanied by their parents).
Compliance is excellent: a mere 2% of our 132 followed-
up patients do not return for control visits. Between
visits, professional support is available to patients via tel-
ephone or e-mail and uninterrupted exchange of infor-
mation is maintained with the family practitioner or
pediatrician of the patient.
The diagnosis, management, and follow up of pediatric
patients with HAE-C1-INH are different from those of
adults. Familiarity with specific, childhood properties is
indispensable to making an accurate diagnosis, choosing
the most appropriate therapy, and shaping the pediatric
patients’ lifestyle to enable them to live a fuller life simi-
lar to their healthy peers.
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